Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Depreciation & Amortization (CF) (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Depreciation & Amortization (CF) data on record, last reported at $120000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 44.58% year-over-year to $120000.0; the TTM value through Dec 2025 reached $460000.0, down 8.0%, while the annual FY2025 figure was $460000.0, 8.0% down from the prior year.
  • Depreciation & Amortization (CF) reached $120000.0 in Q4 2025 per VRDN's latest filing, up from $110000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $145000.0 in Q1 2024 and bottomed at $12000.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $93000.0, with a median of $111500.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 60.94% in 2021, then surged 1075.0% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $12000.0 in 2021, then soared by 1075.0% to $141000.0 in 2022, then fell by 9.22% to $128000.0 in 2023, then tumbled by 35.16% to $83000.0 in 2024, then surged by 44.58% to $120000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $120000.0 in Q4 2025, $110000.0 in Q3 2025, and $113000.0 in Q2 2025.